Showing posts with label Customized Peptide Synthesis Market. Show all posts
Showing posts with label Customized Peptide Synthesis Market. Show all posts

Synthesis of Custom Peptides Boosting Drug Development

Presently, the pharmaceutical sector is synthesizing peptides through multiple processes, on account of technological advancements. In earlier times, peptides were produced with the help of natural sources. For instance, adrenocorticotropic hormone (ACTH) was developed from porcine and bovine pituitary, and insulin was derived from bovine and canine pancreas. These manufacturing processes were time consuming and resulted in low production. However, with innovations in technology, biopharmaceutical companies have started creating synthetic peptides like vasopressin, leuprorelin, oxytocin, and octreotide with the help of solid-phase peptide synthesis (SPPS), hybrid and recombinant technology, and solution-phase peptide synthesis (SPS) technologies.

Browse In-depth Competitive landscape of the Customized Peptide Synthesis Market 

Moreover, the surging participation of private and public research institutes in synthetic biology research will accelerate the customized peptide synthesis market at a CAGR of 6.4% during 2019–2024. The market stood at $268.8 million in 2018, and it has the potential to reach $390.0 million by 2024. The increasing participation of research entities will amplify the funding for the development of advanced and innovative bio-based products, to deal with the global health challenges. These research and development (R&D) activities are essentially aimed at producing better drugs for the treatment of chronic diseases.

Apart from pharmaceutical and biotechnology companies and academic and research institutes, contract manufacturing organizations (CMOs) and contract research organizations (CROs) also utilize peptides in large quantities. These entities require a wide range of reagents and equipment to synthesize peptides for antibody production, enzyme profiling, drug discovery, disease research, and biomarker discovery. The reagents utilized by them for the synthesis of peptides include precipitation agents, additives, substrates, and buffers, while the advanced platforms being used for the purpose include the PepTrend system.

According to P&S Intelligence, the Asia-Pacific customized peptide synthesis market will exhibit the fastest growth in the foreseeable future. This will be due to the high-volume usage of peptides in drug discovery, constant technological innovations, hefty R&D funding, and low cost of raw materials in the region. Drug manufacturers in APAC countries are racing to meet the growing requirement for peptide-based drugs to treat chronic diseases. Additionally, new research findings in the region will offer lucrative opportunities for the discovery of peptide-based drugs in the coming years.

Thus, the continuous technological advancements and hefty investments in R&D will lead to a significant rise in the peptide designing and synthesizing activities in the coming years.


Share:

Customized Peptide Synthesis Market Size, Trends and Future Scope


The customized peptide synthesis market is projected to generate a revenue of $390.0 million by 2024 as per a recent P&S Intelligence study. The market is being progressively driven by technological innovations, growing burden of cancer and infectious diseases, increasing investments and funding for protein-based research, and rising research activities in synthetic biology.

There are two main types of products available in the customized peptide synthesis market: reagents and equipment. Among the two, the reagents category is expected to witness the faster growth during the forecast period, registering a CAGR of 6.8%. The reason for such a growth of the domain would be the heavy usage of a wide variety of reagents, including additives, substrates, precipitation agents, buffers, and others.

To Learn More About this report@ http://bit.ly/3cycoSu

Now talking about the application segment, commercial application is expected to be the fastest growing in the customized peptide synthesis market during the forecast period, registering a CAGR of 6.9%. The inclusion of modified amino acids and recent advancements in chemical peptide synthesis have expanded the commercial potential of customized peptides. Moving further to the technology segment, the solid-phase peptide synthesis (SPPS) technology is projected to gain the most ground during 2019–2024, advancing at a CAGR of 6.9%.


New research findings would give the customized peptide synthesis market players a great opportunity to discover new drugs derived from peptides. For instance, in 2017, the anorectic effect of PYY3–36, which is a fragment of peptide YY, in rats was reported by scientists at Takeda Pharmaceuticals Company Ltd. Further, China Medical System Holdings Limited developed XinHouSu, an injectable recombinant human brain natriuretic peptide, to treat acute heart failure. XinHouSu, which is currently available only in China, collected $62.3 million in revenue in 2017, which amounted to an 18.9% growth from 2016.

Such significant discoveries based on intensive research are projected to help in the growth of the customized peptide synthesis market in Asia-Pacific (APAC). During the forecast period, the market in APAC is predicted to advance at a CAGR of 7.9%. The growth would be mainly driven by low raw material prices, technological advancements, increasing research activities in life sciences, rising use of peptides in drug discovery, and availability of funds for research and development.
Share:

Popular Posts